Well not exactely correct. Bind makes Accurins, those Accurins allow drugs to work better. Rather than getting chemo and disrupting your entire body and nuking a whole area, Accurins will allow just the tumor to get the drug, simply to pinpoint the attack. Will be very successful but will eventually be bought. A large chunk is in my accounts now. Sold out of all my OMED last week after is more than doubled since it ran way past its target and price Celgene is buying shares at. Money has been funneled again to this stock and will wait for it to double or better. Biotech is good, biotech's drugs delivered with BIND accurins is better. Potentially huge.
Such silly nonsense. I truly hope you're not short. Look at a Mon-Th chart...
The smart money is flowing in, not out. Not short but long..
So nice to wake up to OMED! What the heck, sold it all at 100% and now I've had a chance to jump all over the BofA upgrade. Still think it gets bought.
No buybacks, that would be a big negative not a good thing. Cash, of which they have $900 million, is far and away better used on R&D, smaller acquisitions, employee training or bonuses. Getting rid of cash is not a signof anything other than youreyou're out of ideas.
Will wait for it to turn green before buying more... March calls look good here though.
Proofreading is not my thing it seems; should have read "Destruction of shareholder value as well as Ken and Michael Xies own fortunes...
Agreed, As a longer term shareholder and one of size I'd like to see some changes from the top down here. Destruction of shareholder value as Ken and Michael Xies own fortunes. They seem to have lost near $58 million on Friday let alone having their company miss a huge market run over the past few years. They of course hold the wild card here and that is the ability to make a call and simply sell to ORCL, IBM, HP or countless others that are willing.
Great technology but not run to increase shareholder wealth or their own, which is weird. I think Rubaie took the job expecting to have the company bought by the end of the year and never intended to stay long term. Oh well, time to right the ship from the top down starting Monday. Find a much better MARKETING head, great coo, and top notch cfo, there's a bunch available. And sprinkle around some year end employee Christmas bonuses to keep them happy or make them happier.
But at $17 its an easy pick to make outsized returns, just don't expect them to start rolling in Monday. Still expect a buyout maybe just not by end of year.
Stock is basically flat since after he arrived and we've missed this giant market move. He was not the great savior the analysts painted him to be, just a placeholder before they sell this company. Now is the time Xies, 900 MM cash, 3.3x '13 sales, make a good move. I'm sure theres a buyer. This departure means nothing to an acquiring company and the move down is a bit crazy but typical. I added a big handful of March 17 calls here. The move down hurt but it's an opportunity for sure. Of course it'll be a better one Monday in the 16s.
Hopefully they'll right this ship, they're losing paper millions pretty fast, me too.
Sentiment: Strong Buy
Yes, no time soon. Doubled from the ipo pricing, now 15% below it, could go to $100 in an instant on news of a breakthrough. Not enough history for any pit to take on risk associated. If it goes lower buy more, if it goes higher, you're in the right place. This is the right place as compared to all these newly minted bio ipo's jumping around.
Will keep stored away in the IRA and regular accounts and check back in a year or so. Would anticipate finding this much much higher in the future. Giving it a 5 year time frame and expect REGN type move toward the end of that period.
Waiting for DEA approval? It'll be a long wait. A better strategy would be to buy now, far below the IPO price, and closer to cash levels and wait...wait for FDA approval down the road. This is one,along with OMED, you want to see in 10 years. See REGN for a case study. As for you and the DEA, get your terms straight if your going to be in biotech stocks.
This is silly. In a consolidating market the first to go FTNT, well second, there was FIRE. It would be a company with, at this time, $900 million is cash and equivelants and trading at 4.5x '14 sales. Not FEYE at 20X '14 sales and not even a fraction of that cash...which would fund part of the purchase price. If this really is a consolidating market, which I believe it is, FTNT goes next. Are they holding out for $35? The teens aren't doing me or the Xie's any favors.
Analyst Shaul Eyal comments, "We are initiating coverage of FireEye, a leading provider of specialized threat analysis protection solutions, with a Perform rating. While we do like FEYE's market position, long-term market drivers and growth profile, current valuation at 20x our FY14E EV/Rev (4.5x its peer average) suggests much of the good news is already priced into shares. We view FEYE as a potentially attractive acquisition candidate in a consolidating security market, but at this juncture we would await a better entry position to become more constructive."
Not short at all. Have been selling puts at the right time for income. Would get long. Need jnpr to get settled first. FTNT will be gone by then i bet.
Not a good strategy if you're goal is to make money. I've been selling puts since its crash months back and that has been paying quite handsomely. If you blhad been buying puts over that period you have lost all of that. This stock cratered, has found a bottom, and is now rebuilding. Just go long stock or sell out of money puts and if you get put stock it'll be a bunch lower than it is now.
The last sentence, where were the big wins and new customer announcements? Assume they'll be coming soon...
I think the fact that they guided down q4 numbers has left a few people somewhat surprised. I'd chalk this up to gamesmanship. The new CFO couldn't pull the fiscal yr in on his first call, q2, and had to wait until Wednesday. I think they want to constantly beat numbers by a good margin so the stock moves in the future. Short term pain for a long term gain. Underpromise, over deliver. Worked that way at his last co, Ariba.
I still like the stock here and can't see selling, acquisition risk is too great. Any given day this could open in the 30's. I think this was Cisco's first call but were rebuffed and went to the number 2 in FIRE. Xie wants to build it to a much larger company before selling... unless it's a monster offer. With over $800 million cash, decent growth, and the ever present potential sale I'll stay long and sell calls at the opportune time.
Someone must know something interesting and they are pumping massive bucks into calls. Gunner looks correct to say this buyer probably used the faulty yahoo finance to get their earnings date which was listed as last week. They lost a ton on those trades and look to be making up for it tomorrow. I added a bunch of Oct 21 calls Friday . Looks like a good trade as of now. If numbers smoke estimates the option buyer will make a killing.
To help you get your bearing on FTNT and Cramer, stock wasn't anywhere near your noted price in the past 3 years. Was more like mid 18's. Still looking for 23-24 in 24 hrs.